<div id="readability-page-1">04:17 PM EST, 12/18/2025 (MT Newswires) -- Tilray Brands ( TLRY ) unit Tilray Medical said Thursday it plans to advance its US medical cannabis operations after federal cannabis rescheduling and related regulatory updates.The company said that, in conjunction with the regulatory changes, it will form Tilray Medical USA.&#34;We support President Trump's decision to reschedule cannabis as a constructive and necessary evolution of US federal policy,&#34; said Tilray Brands ( TLRY ) Chief Executive Irwin Simon.President Donald Trump on Thursday signed an executive order to ease restrictions on marijuana in a move that the White House said would pave the way for conducting medical research on the drug.Trump's order directs Attorney General Pamela Bondi to reclassify marijuana as a Schedule III drug under the Controlled Substance Act, according to a White House fact sheet. Marijuana is currently controlled as a Schedule I substance, which includes drugs with no accepted medical use and a high potential for abuse. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

TLRY

Tilray Brands' unit, Tilray Medical, plans to expand its US medical cannabis operations following federal cannabis rescheduling and regulatory updates. This move aligns with President Trump's executive order to reclassify marijuana as a Schedule III drug, facilitating medical research. Tilray supports this policy change as a positive step in US federal policy evolution.

Tilray Brands Unit to Accelerate US Medical Cannabis Operations After Regulatory Developments